Kassem NM, EL Zawam H, Kassem HA, EL Nahas T, El Husseiny NM, Abd El Azeeim H. A descriptive study of plasma cell dyscrasias in Egyptian population. J Egypt Natl Cancer Inst. 2014;26:67–71.
Article
Google Scholar
Walker BA, Boyle EM, Wardell CP, Murison A, Begum DB, Dahir NM, et al. Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. J Clin Oncol. 2015;33:3911–20.
Article
CAS
PubMed
Google Scholar
Hu Y, Chen W, Wang J. Progress in the identification of gene mutations involved in multiple myeloma. Onco Targets Ther. 2019;12:4075–80.
Article
CAS
PubMed
Google Scholar
Abd El Kader Y, Emera G, Safwat E, Kassem H, Kassem N. The KRAS StripAssay for detection of KRAS mutation in Egyptian patients with colorectal cancer (CRC): a pilot study. J Egypt Natl Cancer Inst. 2013;25:37–41.
Article
Google Scholar
Hashem AM, Fahmy HM, Abdo ES, et al. Prevalence of occult hepatitis C virus infection in patients with multiple myeloma. Med J Cairo Univ. 2015;83:507–13.
Google Scholar
Bird SA, Boyd K. Multiple myeloma: an overview of management. Palli Care Social Practice. 2019;13:1–13.
Google Scholar
Globocan 2018. https://gco.iarc.fr/today/data/factsheets/populations/818-egypt-fact-sheets.pdf.
Petruzziello A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C. Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol. 2016;22(34):7824–40.
Article
PubMed
Google Scholar
El-Ghitany EM. Hepatitis C virus infection in Egypt: current situation and future perspective. J High Inst Public Health. 2019;49(1):1–9.
Article
Google Scholar
Talima S, Kassem H, Kassem N. Chemotherapy and targeted therapy for breast cancer patients with hepatitis C virus infection. Breast Cancer. 2019;26:154–63.
Article
PubMed
Google Scholar
Li Y, Li Y, Zhang L, Li W. Hepatitis C virus infection and risk of multiple myeloma: evidence from a meta-analysis based on 17 case-control studies. J Viral Hepat. 2017;24:1151–9.
Article
CAS
PubMed
Google Scholar
Farawela H, Khorshied M, Shaheen I, Gouda H, Nasef A, Abulata N, et al. The association between hepatitis C virus infection, genetic polymorphisms of oxidative stress genes and B-cell non-Hodgkin’s lymphoma risk in Egypt. Infect Genet Evol. 2012 Aug;12(6):1189–94.
Article
CAS
PubMed
Google Scholar
Teng CJ, Liu HT, Liu CY, et al. Chronic hepatitis virus infection in patients with multiple myeloma: clinical characteristics and outcomes. Clinics (Sao Paulo, Brazil). 2011;66:2055–61.
Article
Google Scholar
McGovern BH, Birch CE, Bowen MJ, Reyor LL, Nagami EH, Chung RT, et al. Improving the diagnosis of acute hepatitis C virus infection with expanded viral load criteria. Clin Infect Dis. 2009;49:1051–60.
Article
PubMed
Google Scholar
Bianchi G, Munshi NC. Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood. 2015;125:3049–58.
Article
CAS
PubMed
Google Scholar
Cavanna L, Sbolli G, Tanzi E, Romanò L, Civardi G, Buscarini E, et al. High prevalence of antibodies to hepatitis C virus in patients with lymphoproliferative disorders. Haematologica. 1995;80:486–7.
CAS
Google Scholar
Musto P, Dell’Olio M, Carotenuto M, Mangia A, Andriulli A. Hepatitis C virus infection: a new bridge between hematologists and gastroenterologists? Blood. 1996;88:752–4.
Article
CAS
Google Scholar
Takeshita M, Sakai H, Okamura S, Higaki K, Oshiro Y, Uike N, et al. Prevalence of hepatitis C virus infection in cases of B-cell lymphoma in Japan. Histopathology. 2006;48:189–98.
Article
CAS
Google Scholar
Silvestri F, Pipan C, Barillari G, Zaja F, Fanin R, Infanti L, et al. Prevalence of hepatitis C virus infection in patients with lymphoproliferative disorders. Blood. 1996;87:4296–301.
Article
CAS
PubMed
Google Scholar
Veneri D, Franchini M, Zanotti R, Frattini F, Randon F, Rinaldi M, et al. Prevalence of hepatitis C virus infection among patients with lymphoproliferative disorders: a single center survey. Am J Hematol. 2007;82:1031.
Article
PubMed
Google Scholar
Anderson LA, Pfeiffer R, Warren JL, Landgren O, Gadalla S, Berndt SI, et al. Hematopoietic malignancies associated with viral and alcoholic hepatitis. Cancer Epidemiol Biomark Prev. 2008;17:3069–75.
Article
Google Scholar
Okan V, Yilmaz M, Bayram A, Kis C, Cifci S, Buyukhatipoglu H, et al. Prevalence of hepatitis B and C viruses in patients with lymphoproliferative disorders. Int J Hematol. 2008;88:403–8.
Article
PubMed
Google Scholar
De Rosa G, Gobbo ML, De Renzo A, Notaro R, Garofalo S, Grimaldi M, et al. High prevalence of hepatitis C virus infection in patients with B-cell lymphoproliferative disorders in Italy. Am J Hematol. 1997;55:77–82.
Article
PubMed
Google Scholar
Matsuo K, Kusano A, Sugumar A, Nakamura S, Tajima K, Mueller NE. Effect of hepatitis C virus infection on the risk of non-Hodgkin’s lymphoma: a meta-analysis of epidemiological studies. Cancer Sci. 2004;95:745–52.
Article
CAS
PubMed
Google Scholar
Dai B, Chen AY, Corkum CP, et al. Hepatitis C virus upregulates B-cell receptor signaling: a novel mechanism for HCV-associated B-cell lymphoproliferative disorders. Oncogene. 2016;35:2979–90.
Article
CAS
PubMed
Google Scholar
Mahale P, Thomas SK, Kyvernitakis A, Torres HA. Management of multiple myeloma complicated by hepatitis C virus reactivation: the role of new antiviral therapy. Open Forum Infec Dis. 2016;3:ofv211.
Article
Google Scholar
Henry SD, Metselaar HJ, Van Dijck J, Tilanus HW, Van Der Laan LJ. Impact of steroids on hepatitis C virus replication in vivo and in vitro. Ann N Y Acad Sci. 2007;1110:439–47.
Article
CAS
PubMed
Google Scholar
Rance E, Tanner JE, Alfieri C. Inhibition of IκB kinase by thalidomide increases hepatitis C virus RNA replication. J Viral Hepat. 2012;19:e73–80.
Article
CAS
PubMed
Google Scholar
Mahale P, Okhuysen PC, Torres HA. Does chemotherapy cause viral relapse in cancer patients with hepatitis C infection successfully treated with antivirals? Clin Gastroenterol Hepatol. 2014;12:e1.
Article
Google Scholar